Research programme: seasonal influenza nanoparticle vaccine - Novavax

Drug Profile

Research programme: seasonal influenza nanoparticle vaccine - Novavax

Alternative Names: Influenza nanoparticle vaccine - Novavax

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Novavax
  • Class Antivirals; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 02 Jun 2016 Preclinical trials in Influenza virus infections (Prevention) in USA (Parenteral)
  • 02 Jun 2016 Novavax plans a phase I/II trial for Influenza viral infections
  • 01 Mar 2011 Novavax awarded contract from US Department of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS BARDA) for vaccine development in Influenza virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top